Society of Gynecologic Oncology publishes practice statement on SCR in recurrent ovarian cancer
Best practice is an elusive concept. So as to promote it, the Society of Gynecologic Oncology (SGO) provides guidance, through practice statements, . This week the SGO issued a guide for patients and surgeons when contemplating secondary cytoreductive surgery (SCR) for women with recurrent ovarian cancer.
Practice statements are based on clinical evidence from randomised trials. In the case of SCR there is a clinical dilemma. From the trials it is clear that for those women whose surgery results in complete clearance there is a survival benefit when compared to women who do not have the surgery. However, when the clearance is incomplete there is evidence that survival is worse than if there had been no surgery.
The SGO does not unreservedly support the use of SCR. It suggests that every effort should be made to achieve complete clearance, and that patient selection prior to surgery, so as to make this more likely, is essential.
No comments:
Post a Comment